Intravenous immunoglobulin therapy for neuromuscular disorders

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Treatment of specific immune-mediated neuromuscular disorders involves consideration of many factors including severity of illness, concurrent medical problems, supportive therapies, and immune-modulating therapies. Many immune-modulating therapies are available, including steroids, an increasing number of immunosuppressive drugs, plasmapheresis, and intravenous immunoglobulin (IVIG). Deciding on which immune-modulating therapy involves selecting from those with proven efficacy for a specific disorder and global considerations of which therapies are most appropriate for an individual patient's circumstances. IVIG has become a commonly used therapy as it is well tolerated, easily administered, and is often efficacious with a relatively rapid action. IVIG has become a first-line therapy for several immune-mediated demyelinating polyneuropathies and may play a role in treating exacerbations of myasthenia gravis and selected chronic treatment-refractory cases of Lambert-Eaton myasthenic syndrome, dermatomyositis, and polymyositis.

Original languageEnglish (US)
Pages (from-to)340-346
Number of pages7
JournalSeminars in Neurology
Volume27
Issue number4
DOIs
StatePublished - Sep 2007

Fingerprint

Passive Immunization
Intravenous Immunoglobulins
Therapeutics
Lambert-Eaton Myasthenic Syndrome
Dermatomyositis
Plasmapheresis
Polyneuropathies
Myasthenia Gravis
Immunosuppressive Agents
Steroids

Keywords

  • Chronic inflammatory demyelinative polyneuropathy
  • Dermatomyositis
  • Guillain-Barré syndrome
  • Intravenous immunoglobulin
  • Lambert-Eaton myasthenic syndrome
  • Multifocal motor neuropathy
  • Myasthenia gravis
  • Neuromuscular disorders
  • Polymyositis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Intravenous immunoglobulin therapy for neuromuscular disorders. / Ross, Mark A.

In: Seminars in Neurology, Vol. 27, No. 4, 09.2007, p. 340-346.

Research output: Contribution to journalArticle

@article{f20cb2ff35e949a5ab870c4042240b86,
title = "Intravenous immunoglobulin therapy for neuromuscular disorders",
abstract = "Treatment of specific immune-mediated neuromuscular disorders involves consideration of many factors including severity of illness, concurrent medical problems, supportive therapies, and immune-modulating therapies. Many immune-modulating therapies are available, including steroids, an increasing number of immunosuppressive drugs, plasmapheresis, and intravenous immunoglobulin (IVIG). Deciding on which immune-modulating therapy involves selecting from those with proven efficacy for a specific disorder and global considerations of which therapies are most appropriate for an individual patient's circumstances. IVIG has become a commonly used therapy as it is well tolerated, easily administered, and is often efficacious with a relatively rapid action. IVIG has become a first-line therapy for several immune-mediated demyelinating polyneuropathies and may play a role in treating exacerbations of myasthenia gravis and selected chronic treatment-refractory cases of Lambert-Eaton myasthenic syndrome, dermatomyositis, and polymyositis.",
keywords = "Chronic inflammatory demyelinative polyneuropathy, Dermatomyositis, Guillain-Barr{\'e} syndrome, Intravenous immunoglobulin, Lambert-Eaton myasthenic syndrome, Multifocal motor neuropathy, Myasthenia gravis, Neuromuscular disorders, Polymyositis",
author = "Ross, {Mark A}",
year = "2007",
month = "9",
doi = "10.1055/s-2007-985331",
language = "English (US)",
volume = "27",
pages = "340--346",
journal = "Seminars in Neurology",
issn = "0271-8235",
publisher = "Thieme Medical Publishers",
number = "4",

}

TY - JOUR

T1 - Intravenous immunoglobulin therapy for neuromuscular disorders

AU - Ross, Mark A

PY - 2007/9

Y1 - 2007/9

N2 - Treatment of specific immune-mediated neuromuscular disorders involves consideration of many factors including severity of illness, concurrent medical problems, supportive therapies, and immune-modulating therapies. Many immune-modulating therapies are available, including steroids, an increasing number of immunosuppressive drugs, plasmapheresis, and intravenous immunoglobulin (IVIG). Deciding on which immune-modulating therapy involves selecting from those with proven efficacy for a specific disorder and global considerations of which therapies are most appropriate for an individual patient's circumstances. IVIG has become a commonly used therapy as it is well tolerated, easily administered, and is often efficacious with a relatively rapid action. IVIG has become a first-line therapy for several immune-mediated demyelinating polyneuropathies and may play a role in treating exacerbations of myasthenia gravis and selected chronic treatment-refractory cases of Lambert-Eaton myasthenic syndrome, dermatomyositis, and polymyositis.

AB - Treatment of specific immune-mediated neuromuscular disorders involves consideration of many factors including severity of illness, concurrent medical problems, supportive therapies, and immune-modulating therapies. Many immune-modulating therapies are available, including steroids, an increasing number of immunosuppressive drugs, plasmapheresis, and intravenous immunoglobulin (IVIG). Deciding on which immune-modulating therapy involves selecting from those with proven efficacy for a specific disorder and global considerations of which therapies are most appropriate for an individual patient's circumstances. IVIG has become a commonly used therapy as it is well tolerated, easily administered, and is often efficacious with a relatively rapid action. IVIG has become a first-line therapy for several immune-mediated demyelinating polyneuropathies and may play a role in treating exacerbations of myasthenia gravis and selected chronic treatment-refractory cases of Lambert-Eaton myasthenic syndrome, dermatomyositis, and polymyositis.

KW - Chronic inflammatory demyelinative polyneuropathy

KW - Dermatomyositis

KW - Guillain-Barré syndrome

KW - Intravenous immunoglobulin

KW - Lambert-Eaton myasthenic syndrome

KW - Multifocal motor neuropathy

KW - Myasthenia gravis

KW - Neuromuscular disorders

KW - Polymyositis

UR - http://www.scopus.com/inward/record.url?scp=34548354486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548354486&partnerID=8YFLogxK

U2 - 10.1055/s-2007-985331

DO - 10.1055/s-2007-985331

M3 - Article

VL - 27

SP - 340

EP - 346

JO - Seminars in Neurology

JF - Seminars in Neurology

SN - 0271-8235

IS - 4

ER -